Tags: Cancer | trebananib | ovarian cancer | chemotherapy drugs

Ovarian Cancer Drug Shows Promise

Wednesday, 12 Jun 2013 12:01 PM

 


Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
 
The company said the drug had met its primary goal in the trial, which is the first of three for the new treatment.
 
Amgen said that while it was working on the primary analysis of overall survival for 2014, it saw a favorable survival trend in an interim analysis.
 
Shares in Amgen were up slightly $98.25 in Nasdaq morning trading.

© 2015 Thomson/Reuters. All rights reserved.

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Pancreatic Cancer Researchers Get Closer to 'Big Break'

Friday, 30 Jan 2015 16:25 PM

Scientists are working to find new ways to treat pancreatic cancer, one of the deadliest types of cancer in the United S . . .

GMO Food Labels in High Demand but Provide Little Certainty

Friday, 30 Jan 2015 16:21 PM

While a national debate rages over labeling foods that contain genetically modified ingredients, many products now certi . . .

Kidney Stones Raise Heart Disease Risk: Study

Friday, 30 Jan 2015 16:20 PM

Some people who develop recurring kidney stones may also have high levels of calcium deposits in their blood vessels, an . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved